Ongoing Clinical Trials for Post Procedural Pulmonary Embolism
There is currently 1 ongoing clinical trial investigating treatment options for post procedural pulmonary embolism. This trial is examining whether rosuvastatin, a medication typically used to lower cholesterol, can help prevent recurrent blood clots in patients who have experienced pulmonary embolism or deep vein thrombosis.
Clinical trial locations
- France
- Norway
Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism
This trial is investigating whether rosuvastatin calcium, a medication commonly known as a statin, can help reduce the occurrence of recurrent blood clots in patients who have already experienced pulmonary embolism or deep vein thrombosis. While statins are typically used to lower cholesterol levels, researchers are exploring whether they may also help prevent further blood clot events by reducing inflammation and stabilizing blood vessel walls.
Main inclusion criteria: Patients eligible for this study must have a confirmed diagnosis of symptomatic proximal leg deep vein thrombosis (a blood clot in the deep veins of the upper leg) or pulmonary embolism (a blockage in the lung arteries) that was diagnosed within the last 30 days. Both male and female patients can participate.
Main exclusion criteria: Patients cannot join the study if they are pregnant or breastfeeding, have severe allergic reactions to the study medication, have severe liver or kidney disease, have had recent major surgery or significant bleeding problems, have uncontrolled high blood pressure, or have a history of alcohol or drug abuse. Those taking medications that might interfere with the study drug or who have certain uncontrolled heart rhythm problems are also excluded.
Trial focus and goals: The study is designed to determine whether taking rosuvastatin calcium can lower the rate of major blood clot events compared to a placebo (an inactive substance). Participants will be randomly assigned to receive either the active medication (20 mg rosuvastatin calcium tablet taken orally) or a placebo. Throughout the study, researchers will monitor participants for recurrent blood clots in the legs or lungs, as well as other health outcomes such as post-thrombotic syndrome (a condition that can develop after a blood clot), heart attacks, or strokes. The trial is expected to continue until the end of 2027.
Investigational drug: The medication being tested is rosuvastatin calcium, administered as a 20 mg oral tablet. Rosuvastatin works by inhibiting an enzyme called HMG-CoA reductase, which is involved in cholesterol production in the liver. This mechanism may also lead to reduced inflammation and more stable blood vessel walls, potentially helping to prevent recurrent blood clot events.
Summary
Currently, only one clinical trial is actively recruiting patients with post procedural pulmonary embolism. This study is being conducted in France and Norway and represents an innovative approach to preventing recurrent blood clots by repurposing a well-known cholesterol-lowering medication. The trial focuses on rosuvastatin calcium and will run until late 2027, aiming to provide important insights into whether statins can offer additional protection beyond traditional anticoagulation therapy for patients who have experienced venous thromboembolism events.
